Bionano Genomics, INC Form 4 insider transactions

Bionano Genomics' Chief Medical Officer, Alka Chaubey, reported a routine disposition of 24 shares of common stock to cover tax withholding obligations related to the vesting of a restricted stock unit award.

Bionano Genomics' President and CEO, R. Erik Holmlin, reported the withholding of 75 shares of common stock valued at $3.69 per share on June 3, 2025, to cover tax obligations related to a vested RSU award.

Bionano Genomics' General Counsel, Jonathan V. Dixon, reported a routine disposition of 25 shares of common stock to cover tax obligations upon the vesting of Restricted Stock Units.

Jonathan V. Dixon, General Counsel of Bionano Genomics, reports the acquisition of stock options.

Mark Adamchak, Principal Accounting Officer of Bionano Genomics, acquired stock options for 3,029 shares of common stock on March 14, 2025.

CEO R. Erik Holmlin reports acquisition of shares through stock options and withholding of shares for tax obligations related to vested PSUs.

Mark Oldakowski, Chief Operating Officer of Bionano Genomics, acquired stock options on March 14, 2025, according to a Form 4 filing with the SEC.

Alka Chaubey, Chief Medical Officer of Bionano Genomics, acquired stock options exercisable for 6,966 shares of common stock on March 14, 2025.

Mark Oldakowski, COO of Bionano Genomics, reports the withholding of 20 common shares to cover tax obligations related to vested RSUs, following a 1-for-60 stock split.

Jonathan V. Dixon, General Counsel of Bionano Genomics, reports the withholding of shares for tax obligations and the impact of a 1-for-60 stock split on his holdings.

CEO Erik Holmlin reports changes in Bionano Genomics beneficial ownership due to a stock split, RSU vesting, and tax withholding.

Alka Chaubey, Chief Medical Officer of Bionano Genomics, reports changes in beneficial ownership due to a stock split and the vesting of Restricted Stock Units (RSUs) used to cover tax obligations.

Mark Adamchak, Principal Accounting Officer at Bionano Genomics, reports the withholding of shares to cover tax obligations related to vested RSUs and the impact of a prior stock split.

Mark Adamchak, Principal Accounting Officer of Bionano Genomics, acquired 17,500 stock options on October 1, 2024, at an exercise price of $0.42.

Mark Oldakowski, COO of Bionano Genomics, reports the withholding of shares to cover tax obligations related to a vested RSU award.

Alka Chaubey, Chief Medical Officer of Bionano Genomics, reports the withholding of 3,075 shares to cover tax obligations related to a vested RSU award.

Aleksandar Rajkovic, a director at Bionano Genomics, acquired 30,000 stock options on June 18, 2024, according to a recent SEC Form 4 filing.

Director Albert Luderer acquired 30,000 stock options in Bionano Genomics, Inc. on June 18, 2024.

Kristiina Vuori, a director at Bionano Genomics, acquired stock options exercisable for 30,000 shares of common stock on June 18, 2024.

Director David L. Barker acquired 30,000 stock options in Bionano Genomics, Inc. on June 18, 2024.

Director Wong Vincent Jung-Fai acquired stock options in Bionano Genomics, Inc. on June 18, 2024.

Director Hannah Mamuszka acquired 30,000 stock options in Bionano Genomics on June 18, 2024.

Director Christopher J. Twomey acquired 30,000 stock options in Bionano Genomics on June 18, 2024, according to a Form 4 filing with the SEC.

Yvonne Linney, a director at Bionano Genomics, acquired 30,000 stock options on June 18, 2024, according to a recent SEC filing.

Mark Oldakowski, Chief Operating Officer of Bionano Genomics, reports acquisition of shares and stock options.

Gulsen Kama, CFO of Bionano Genomics, was granted stock options and restricted stock units (RSUs) on June 3, 2024, as disclosed in a Form 4 filing with the SEC.

R. Erik Holmlin, CEO of Bionano Genomics, reports the acquisition of restricted stock units and stock options.

Jonathan V. Dixon, General Counsel of Bionano Genomics, reports the acquisition of stock options and restricted stock units.

Alka Chaubey, Chief Medical Officer of Bionano Genomics, reports the acquisition of stock options and restricted stock units.

Alka Chaubey, Chief Medical Officer of Bionano Genomics, reports the withholding of 1,081 shares to cover tax obligations related to a vested RSU award.